Back to top

Analyst Blog

Switzerland-based pharmaceutical company, Novartis AG (NVS - Snapshot Report) recently announced positive phase II data on its pipeline candidate, LCZ696, from the PARAMOUNT study.

The study showed significant reduction in a key indicator of morbidity and mortality in patients suffering from chronic heart failure with preserved ejection fraction (HF-PEF).

Data from the phase II PARAMOUNT study showed that LCZ696 achieved its primary endpoint. After 12 weeks of treatment with LCZ696, there was a reduction of more than 23% in the stress maker NT-proBNP, compared to treatment with Diovan (valsartan).

The study also revealed that treatment with LCZ696 helped in the reduction of the left atrial size in patients after 36 weeks. Novartis reported that LCZ696 was well tolerated.

Novartis is currently studying LCZ696 in a phase III trial, PARADIGM-HF for the treatment of heart failure with reduced ejection fraction (HF-REF). Data from an earlier phase II trial evaluating LCZ696 showed significant reduction in blood pressure versus Diovan. Another phase III trial for the first-line treatment of hypertension has been launched in Asia.

Already approved hypertension treatments include Takeda Pharmaceutical Company Limited’s (TKPYY) Edarbi and Merck & Co’s (MRK - Analyst Report) Cozaar.

Our Recommendation

We are pleased with Novartis’ wide range of products. We also note that there is no currently approved medication for the reduction of morbidity and mortality in HF-PEF patients. Up to half of the 20 million Europeans and Americans afflicted by heart failure are also suffering from this difficult-to-treat variant.  

Currently, we have a Neutral recommendation on Novartis. The company carries a Zacks #3 Rank (“Hold” rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%